A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily Via Inhalation, for 2 Weeks, in Adults With Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
Latest Information Update: 25 Jun 2025
At a glance
- Drugs AZD 8630 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 18 Jun 2025 Planned End Date changed from 28 May 2025 to 27 Jun 2025.
- 18 Jun 2025 Planned primary completion date changed from 28 May 2025 to 27 Jun 2025.
- 18 Jun 2025 Status changed from recruiting to active, no longer recruiting.